Futu Holdings: Navigating Regulatory Challenges with Strong Growth Prospects
Finance

Futu Holdings: Navigating Regulatory Challenges with Strong Growth Prospects

authorBy Mariana Mazzucato
DateJul 03, 2026
Read time3 min

Futu Holdings Limited (FUTU) has experienced a significant decline in its share price this year, primarily due to ongoing regulatory scrutiny from the China Securities Regulatory Commission (CSRC). While approximately 20% of the company's revenue and 13-17% of its customer accounts are affected by these regulations, the firm is well-positioned to mitigate these challenges through its burgeoning corporate services and robust expansion in Hong Kong's Equity Capital Market (ECM). The current market valuation, therefore, presents a compelling buying opportunity, with a target price range of $115 to $128 per share, reflecting an upside driven by underappreciated aspects of its business.

Analyst consensus for Futu's 2027 revenue and earnings per share (EPS) appears to be overly conservative. Our projections indicate a potential revenue of $3.4 billion and an EPS of $12.83, exceeding current market expectations by 5%. This optimistic outlook is largely predicated on the accelerated growth within its corporate services division. While competitive pressures in ASEAN and US markets, alongside potential volatility in Hong Kong and US trading revenues, present notable risks, these are expected to be outweighed by the solid growth trajectory of its corporate services, coupled with a strong return on equity (ROE) ranging between 25-30%.

Corporate Services: A Shield Against Regulatory Headwinds

Futu Holdings is adeptly leveraging its corporate services to counteract the impact of regulatory tightening in mainland China. Despite the CSRC's actions posing challenges to a segment of its business, the expansion into enterprise solutions and the vibrant Hong Kong ECM market are proving to be powerful growth drivers. This strategic pivot highlights Futu's resilience and capacity to adapt to evolving market conditions, ensuring continued revenue streams and client base expansion in less restrictive environments. The firm's ability to diversify its service offerings and geographical reach is key to maintaining its growth trajectory amidst regulatory uncertainties.

The strategic focus on corporate services provides Futu with a crucial buffer against regulatory pressures. These services, including investment banking, wealth management, and employee stock ownership plans, are experiencing rapid adoption and growth, particularly in Hong Kong and other international markets. This diversification not only reduces reliance on the segments affected by Chinese regulations but also taps into new, high-potential revenue streams. The success in these areas is projected to significantly contribute to Futu's overall revenue and profitability, underscoring the intrinsic value of its enterprise segment and positioning it for sustained success.

Financial Outlook and Valuation Potential

Despite the current bearish sentiment reflected in the year-to-date share performance, the underlying financial health and future prospects of Futu Holdings remain strong. Our analysis suggests a notable disconnect between market expectations and the company's intrinsic value, especially considering the potential from its corporate services and ECM activities. The projected incremental revenue of $150–$218 million from these segments alone underscores their importance in driving future growth and mitigating risks associated with regulatory changes. This robust financial outlook supports a bullish rating for Futu, indicating significant upside potential for investors.

The target price of $115–$128 per share is based on a conservative 9–10x forward earnings multiple, reflecting an anticipated 16–28% upside. This valuation takes into account the company's strong ROE, which consistently hovers between 25–30%, demonstrating efficient capital utilization and robust profitability. While market volatility and intense competition in overseas markets remain concerns, the diversified revenue streams, particularly from corporate services, are expected to provide stability and continuous growth. These factors collectively build a strong case for Futu's valuation, indicating that its current market price does not fully reflect its long-term growth potential and operational strengths.

More Articles
Finance
US Treasury Yields React to Employment Data, Signaling Potential for Further Steepening
Recent US payroll data has caused a notable steepening of the Treasury yield curve, particularly at the front end. This shift suggests a continuing trend where longer-dated yields maintain their levels due to rising real yields and decreasing inflation risk, while shorter-dated yields decline. The interplay of these factors indicates an evolving landscape for fixed-income markets.
By Nouriel RoubiniJul 03, 2026
Finance
Micron's Market Surge: A Deep Dive into Valuation and Future Prospects
Micron Technologies has experienced an impressive surge, with its stock price increasing nearly eightfold in a single year. Despite this rapid growth, the company maintains a seemingly modest valuation, trading at approximately 10.5 times its peak quarterly earnings. This analysis explores whether this valuation reflects a sustainable growth trajectory or if underlying risks, such as cyclical market dynamics and potential oversupply, warrant a cautious approach for investors.
By David RubensteinJul 03, 2026
Finance
US Manufacturing Sector Shows Robust Growth in June Despite Fading Optimism
The US manufacturing sector experienced significant growth in output and new orders in June, marking the strongest quarter in nearly five years, according to S&P Global's PMI data. This surge in production, coupled with a decline in employment, indicates an increase in productivity. However, manufacturers anticipate a slowdown in customer purchasing as supply chain concerns related to global conflicts ease, posing potential risks for future production.
By David RubensteinJul 03, 2026
Finance
Travere Therapeutics: Pioneering Rare Kidney Disease Treatment
Travere Therapeutics is emerging as a leader in rare kidney disease treatment, leveraging FILSPARI's strong performance in IgAN and its recent FSGS approval. The company's strategic acquisitions, such as civorebrutinib, and its focus on operational efficiency justify its high valuation. Despite competition in IgAN and potential label limitations, FILSPARI's distinct market position and simplified risk management program are expected to drive continued growth.
By Lisa JingJul 03, 2026
Finance
Chime Financial: Strong Growth Potential Justifies Valuation
Chime Financial (CHYM) receives a 'buy' rating due to its robust member engagement and expanding product offerings, which are expected to boost average revenue per member (ARPAM) and transaction profits. New initiatives like MyPay and Chime Prime are diversifying revenue streams and enhancing member value. Despite a P/E ratio of approximately 22x, the company's rapid earnings growth supports this valuation. Potential risks include credit losses and regulatory shifts.
By David RubensteinJul 03, 2026